Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis-Reference-Cited by-同舟云学术

Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis

Published:2017-11-28 Issue:8 Volume:34 Page:1361-1371
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Siddiqui Mohd Kashif¹,Khurana Inderpreet Singh¹,Budhia Sangeeta²,Hettle Robert²,Harty Gerard³,Wong Schiffon L.⁴

Affiliation:

1. Parexel International (Heron commercialization), Chandigarh, UT, India;

2. Parexel International, London, UK;

3. Merck Serono Ltd, Feltham, Middlesex, UK;

4. EMD Serono Inc., Billerica, MA, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2017.1407303

Reference63 articles.

1. Multiple Sclerosis: Pathogenesis and Treatment

2. Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis. Doc. Ref. EMA/CHMP/771815/2011, Rev. 2. London, UK: European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), 26 March 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf [Last accessed 14 June 2017]

3. Multiple sclerosis

4. Benefit–Risk of Therapies for Relapsing–Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis

5. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis;Multiple Sclerosis Journal;2024-08

2. Long‐Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries;Pharmacoepidemiology and Drug Safety;2024-07

3. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study;Clinical Neurology and Neurosurgery;2024-05

4. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review;Health Economics Review;2024-02-16

5. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation;Autoimmunity Reviews;2024-02